TVARDI THERAPEUTICS, INC.
Income Statement
| Line Item | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $1.5M | $2.6M | $991.0K | $2.1M | $3.0M | $4.9M | $6.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $3.1M | $-9.6M | $4.8M | $6.5M | $22.0M | $28.4M | $25.5M | $30.3M |
| SG&A Expense | $1.2M | $-3.9M | $881.0K | $650.0K | $6.8M | $6.6M | $6.8M | $7.5M |
| Operating Income | $-4.4M | $14.4M | $-5.7M | $-7.2M | $-29.7M | $-32.6M | $-28.9M | $-32.3M |
| Operating Margin | -169.5% | 990.8% | -222.1% | -724.6% | -1,389.5% | -1,085.5% | -593.9% | -466.5% |
| Interest Expense | $558.0K | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-9.6M | $-12.7M | $-5.5M | $-7.0M | $-4.2M | $-32.3M | $-28.0M | $-31.5M |
| Net Margin | -372.9% | -873.3% | -215.7% | -703.8% | -196.8% | -1,076.5% | -576.1% | -454.0% |
| EPS (Basic) | $-1.24 | $4.56 | $-0.71 | $-0.90 | $-6.75 | $-8.22 | $-0.17 | $-0.19 |
| EPS (Diluted) | $-1.24 | $4.56 | $-0.71 | $-0.90 | $-6.75 | $-8.22 | $-0.17 | $-0.19 |
| Shares Outstanding (Basic) | 7.7M | 7.7M | 7.7M | 7.7M | 4.5M | 13.5M | 162.7M | 162.0M |
| Shares Outstanding (Diluted) | 7.7M | 7.7M | 7.7M | 7.7M | 4.5M | 13.5M | 162.7M | 162.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |